Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With a Mechanical Prosthesis.

[1]  J. Eikelboom,et al.  Anticoagulation for Mechanical Heart Valves: Will Oral Factor Xa Inhibitors Be Effective? , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[2]  J. Reiffel.  Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted. , 2017, Circulation.

[3]  Vishesh Kumar,et al.  Mechanical Valve Thrombosis on Rivaroxaban: Are Novel Anticoagulants Really an Option? , 2017, Methodist DeBakey cardiovascular journal.

[4]  R. de Caterina,et al.  Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. , 2017, Journal of the American College of Cardiology.

[5]  Roxana Mehran,et al.  Prosthetic Heart Valve Thrombosis. , 2016, Journal of the American College of Cardiology.

[6]  A. Eisinga,et al.  NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis , 2016, Open Heart.

[7]  J. Mega,et al.  Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments , 2015, The Lancet.

[8]  C. Mestres,et al.  Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[9]  H. Schaff,et al.  Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[10]  S. Connolly,et al.  Dabigatran versus warfarin in patients with mechanical heart valves. , 2013, The New England journal of medicine.

[11]  U. Steinseifer,et al.  Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study , 2011, Journal of Thrombosis and Thrombolysis.

[12]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[13]  Andre Lamy,et al.  Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends , 2009, The Lancet.

[14]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[15]  V. Fuster,et al.  High risk of thromboemboli early after bioprosthetic cardiac valve replacement. , 1995, Journal of the American College of Cardiology.

[16]  D. Fatkin,et al.  Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. , 1994, Journal of the American College of Cardiology.

[17]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.